Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma
← catalyst calendarNCT06667687 · readout ≤ 253 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
21actual
Sites
14
Countries
Australia, Israel, Japan +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-01-16 | actual | When the study began enrolling |
| Primary completion | Apr 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Apr 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2024-10-31 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non-Hodgkin's Lymphoma
Intervention
- Drug: ABBV-291
Primary outcomes
what the primary-completion date above is the date OFPercentage of Participants with Adverse Events (AE)s
measured Up to 74 Months
Percentage of Participants with Dose Limiting Toxicities (DLT)s
measured Up to 74 Months
Percentage of Participants with Clinically Significant Laboratory Values (Chemistry, and Hematology)
measured Up to 74 Months
Percentage of Participants with Clinically Significant Vital Sign Measurements
measured Up to 74 Months
Percentage of Participants with Clinically Significant Electrocardiogram (ECG) Findings
measured Up to 74 Months
Objective Response Rate (ORR)
measured Up to 74 Months
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed